I just read in the NYT about an amyloid-clearing drug called BAN2401 that just reported results of Phase 2 trials (which test the safety and efficacy of a drug). The article starts by singing the praises of the drug, which substantially reduces amyloid scores. However, it then cautions that the drug's ability to slow down cognitive decline was small.
This supports the OP: amyloid may not be the culprit. In a phase 3 trial, the drug may not pan out.
source: nyti.ms/2JWjznT